Estrella Immunopharma Stock Performance
| ESLA Stock | 1.00 0.01 1.01% |
The firm shows a Beta (market volatility) of 0.51, which means possible diversification benefits within a given portfolio. As returns on the market increase, Estrella Immunopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Estrella Immunopharma is expected to be smaller as well. At this point, Estrella Immunopharma has a negative expected return of -0.0977%. Please make sure to confirm Estrella Immunopharma's expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Estrella Immunopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Estrella Immunopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong essential indicators, Estrella Immunopharma is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | Insider Trading | 02/11/2025 |
| Begin Period Cash Flow | 2.5 M |
Estrella |
Estrella Immunopharma Relative Risk vs. Return Landscape
If you would invest 120.00 in Estrella Immunopharma on December 4, 2024 and sell it today you would lose (20.00) from holding Estrella Immunopharma or give up 16.67% of portfolio value over 90 days. Estrella Immunopharma is currently does not generate positive expected returns and assumes 6.5152% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Estrella, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Estrella Immunopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Estrella Immunopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Estrella Immunopharma, and traders can use it to determine the average amount a Estrella Immunopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.015
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ESLA |
Estimated Market Risk
| 6.52 actual daily | 58 58% of assets are less volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Estrella Immunopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Estrella Immunopharma by adding Estrella Immunopharma to a well-diversified portfolio.
Estrella Immunopharma Fundamentals Growth
Estrella Stock prices reflect investors' perceptions of the future prospects and financial health of Estrella Immunopharma, and Estrella Immunopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Estrella Stock performance.
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 15.43 M | ||||
| Shares Outstanding | 36.18 M | ||||
| Price To Book | 49.93 X | ||||
| EBITDA | (7.31 M) | ||||
| Net Income | (7.31 M) | ||||
| Total Debt | 180.7 K | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (16.07 M) | ||||
| Earnings Per Share | (0.24) X | ||||
| Market Capitalization | 53.91 M | ||||
| Total Asset | 4.45 M | ||||
| Retained Earnings | (19.5 M) | ||||
| Working Capital | 4.27 M | ||||
About Estrella Immunopharma Performance
By analyzing Estrella Immunopharma's fundamental ratios, stakeholders can gain valuable insights into Estrella Immunopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Estrella Immunopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Estrella Immunopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.10) | (0.10) | |
| Return On Capital Employed | (0.18) | (0.18) | |
| Return On Assets | (0.10) | (0.10) | |
| Return On Equity | (0.14) | (0.15) |
Things to note about Estrella Immunopharma performance evaluation
Checking the ongoing alerts about Estrella Immunopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Estrella Immunopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Estrella Immunopharma generated a negative expected return over the last 90 days | |
| Estrella Immunopharma has high historical volatility and very poor performance | |
| Estrella Immunopharma has some characteristics of a very speculative penny stock | |
| Estrella Immunopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.31 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Estrella Immunopharma generates negative cash flow from operations | |
| Estrella Immunopharma has a frail financial position based on the latest SEC disclosures | |
| About 72.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Insider Trading |
- Analyzing Estrella Immunopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Estrella Immunopharma's stock is overvalued or undervalued compared to its peers.
- Examining Estrella Immunopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Estrella Immunopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Estrella Immunopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Estrella Immunopharma's stock. These opinions can provide insight into Estrella Immunopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Estrella Stock analysis
When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |